Correlation Between Kronos Bio and Centessa Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Kronos Bio and Centessa Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Kronos Bio and Centessa Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Kronos Bio and Centessa Pharmaceuticals PLC, you can compare the effects of market volatilities on Kronos Bio and Centessa Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Kronos Bio with a short position of Centessa Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Kronos Bio and Centessa Pharmaceuticals.

Diversification Opportunities for Kronos Bio and Centessa Pharmaceuticals

0.2

Correlation Coefficient

Kronos Bio  Centessa Pharmaceuticals

Modest diversification

The 3 months correlation between Kronos and Centessa is 0.2. Overlapping area represents the amount of risk that can be diversified away by holding Kronos Bio and Centessa Pharmaceuticals PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Centessa Pharmaceuticals and Kronos Bio is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Kronos Bio are associated (or correlated) with Centessa Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Centessa Pharmaceuticals has no effect on the direction of Kronos Bio i.e., Kronos Bio and Centessa Pharmaceuticals go up and down completely randomly.

Pair Corralation between Kronos Bio and Centessa Pharmaceuticals

Given the investment horizon of 90 days Kronos Bio is expected to under-perform the Centessa Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Kronos Bio is 1.71 times less risky than Centessa Pharmaceuticals. The stock trades about -0.11 of its potential returns per unit of risk. The Centessa Pharmaceuticals PLC is currently generating about -0.03 of returns per unit of risk over similar time horizon. If you would invest  1,635  in Centessa Pharmaceuticals PLC on December 29, 2024 and sell it today you would lose (184.00) from holding Centessa Pharmaceuticals PLC or give up 11.25% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Kronos Bio  vs.  Centessa Pharmaceuticals PLC

Kronos Bio

Risk-Adjusted Performance

Very Weak

Over the last 90 days Kronos Bio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Centessa Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Centessa Pharmaceuticals PLC has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest unsteady performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Pair Trading with Kronos Bio and Centessa Pharmaceuticals

The main advantage of trading using opposite Kronos Bio and Centessa Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Kronos Bio position performs unexpectedly, Centessa Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Centessa Pharmaceuticals will offset losses from the drop in Centessa Pharmaceuticals' long position.

The idea behind Kronos Bio and Centessa Pharmaceuticals PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.